Literature DB >> 8141694

How vancomycin is used in Australasia--a survey.

S B Duffull1, S T Chambers, E J Begg.   

Abstract

BACKGROUND: Vancomycin serum concentrations have been monitored over the last 30 years in an attempt to avoid dose-dependent toxicity and enhance efficacy. Current literature recommendations for peak and trough concentrations are usually in the range of 20-40 mg/L and 5-10 mg/L, respectively. Literature recommendations regarding the time at which peak concentrations are measured are highly variable, ranging from immediately after the end of the infusion to three hours post-dose. AIMS: To identify how vancomycin dosing is being monitored and assess variability in the current practice.
METHODS: A survey of microbiology departments and infectious disease physicians in major Australasian hospitals was undertaken. The variability in the current practice was assessed by fitting mean recommendations to a two compartment Bayesian model.
RESULTS: Of the 83 (70%) who replied 71 (86%) monitored vancomycin concentrations. Fifty-four percent targeted peak concentrations within the range of 20-40 mg/L, and 73% targeted trough concentrations < or = 10 mg/L. The time of sampling of peak concentrations varied considerably ranging from immediately (12%) to 120 minutes (12%) post-infusion (median 30 minutes [40%]). The concentration-time curves resulting from three sets of mean recommendations ('peaks' drawn at: 0, 30 and 120 minutes aiming for a concentration of 35 mg/L with a trough concentration of 10 mg/L) were modelled using a two compartment Bayesian programme. The predicted true peak (maximum) concentrations ranged from 30 to 86 mg/L, despite aiming for identical target concentrations, indicating marked variation in the actual dosing practice.
CONCLUSIONS: There is thus considerable variation in the practice of vancomycin therapeutic monitoring which has a major effect on dosing. The main contributing factor is the variable timing of sampling peak concentrations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8141694     DOI: 10.1111/j.1445-5994.1993.tb04723.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  3 in total

1.  Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model.

Authors:  S B Duffull; E J Begg; S T Chambers; M L Barclay
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 2.  The therapeutic monitoring of antimicrobial agents.

Authors:  E J Begg; M L Barclay; C J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 3.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.